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Dialysis accelerates  
vascular calcification
Vascular calcification is highly prevalent in dialysis patients and 
arguably part of a complex process that contributes to their high 
rates of morbidity and mortality. A new article describes and quan-
tifies the histology and calcification of vessels among children with 
and without kidney disease. Shroff et al. compared medium-sized 
muscular arteries routinely removed at omentectomy during peri-
toneal dialysis catheter insertion or renal transplantation in 34 
patients with chronic kidney disease (CKD) with mesenteric arter-
ies removed at planned intra-abdominal surgery in six disease-
free age-matched control patients without underlying comorbidity. 
Detailed histology and immunohistochemistry were performed. 
The load of calcium within vessels was significantly elevated in 
patients with CKD both on and not yet on dialysis (Figure). Ves-
sels from patients with CKD not yet on dialysis were histologically 
intact; those from patients receiving dialysis showed evidence of 
extensive vascular smooth muscle cell loss, likely due to apop-
tosis. These vessels also showed increased alkaline phosphatase 
activity and Runx2 and osterix expression, indicating vascular 
smooth muscle cell osteogenic transformation. The deposition of 
fetuin-A and matrix Gla-protein was increased in the vessels of 
dialysis patients and preceded overt calcification. Hydroxyapatite 
nanocrystals were present on electron microscopy within vesicles 
from damaged vascular smooth muscle cells, suggesting a role in 
initiating calcification.
This study confirms the presence of vascular calcification that 
precedes dialysis among children with CKD. Apoptosis of vascular 
smooth muscle cells is a prominent component of the histology 
of vascular calcification among children on dialysis. Whether this 
factor contributes to the initiation of calcification or is an effect 
of the calcification needs to be further examined. Regardless, this 
finding could help identify new therapeutic strategies that target 
vascular calcification, likely a major contributor to morbidity and 
mortality among persons with kidney disease. (Circulation 2008; 
118: 1748–1757; doi:10.1161/CIRCULATIONAHA.108.783738)
Lynda Szczech
Molecular mimicry  
in pauci-immune FNGN
Pauci-immune crescentic focal necrotizing glomerulonephritis 
(FNGN) is an acute inflammatory disease that results in rapid, irre-
versible kidney failure, typically in the context of a systemic small-
vessel vasculitis, such as microscopic polyangiitis or Wegener’s 
granulomatosis. Injury is caused by neutrophils and macrophages 
that localize in glomerular capillaries without detectable immune 
deposits. Despite this, pauci-immune FNGN is thought to be an 
autoimmune disease because of its almost invariable association 
with autoantibodies to neutrophil cytoplasmic antigens (ANCAs). 
ANCAs have proved to be invaluable for diagnosis and monitoring 
of disease activity, and the soluble lysosomal enzymes myeloperoxi-
dase and proteinase-3 have been identified as targets. Antibodies to 
these enzymes activate primed neutrophils and cause neutrophil-
dependent endothelial injury in vitro: administration of antibodies 
to myeloperoxidase has been shown to provoke FNGN in rodents, 
especially when injected together with lipopolysaccharide; anti-
bodies to proteinase-3 have been less effective. However, individu-
als with FNGN have other autoantibodies as well—for example, 
autoantibodies to the extracellular domain of human lysosomal 
membrane protein-2 (LAMP-2)—but their role in the pathogen-
esis of FNGN is unknown. LAMP-2 is a heavily glycosylated type 1 
membrane protein with roles in cell adhesion, autophagocytosis, 
and antigen presentation. In neutrophils, LAMP-2 is integrated into 
the membranes of myeloperoxidase- and proteinase-3-containing 
intracellular vesicles, and thus autoantibodies to human LAMP-2 
give positive results in fluorescence ANCA assays. However, in 
contrast to myeloperoxidase and proteinase-3, LAMP-2 shuttles 
between lysosomes and the cell membrane and is abundant on neu-
trophil and endothelial cell surfaces and hence accessible to circu-
lating antibodies. It is not yet known what initiates autoantibody 
formation in FNGN, but (as Wegener first postulated) bacterial 
infections appear to be involved.
In a recent report, Kain et al. characterized autoantibodies to 
LAMP-2 and found that they are a new ANCA subtype present in 
almost all individuals with FNGN. They found that autoantibodies to 
LAMP-2 are nearly twice as prevalent as those that recognize myeloper-
oxidase or proteinase-3. Furthermore, antibodies to LAMP-2 induced 
pauci-immune FNGN when injected into rats, and a monoclonal anti-
body to human LAMP-2 induced apoptosis of human micro vascular 
Calcium accumulation in the vessel wall begins before dialysis, and factors 
specific to the dialysis milieu trigger accelerated calcification. 
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Immunization with FimH induces FNGN in rats. Normal glomerular 
histology from control rats (left). In rats immunized with FimH, there was 
formation of glomerular crescents (middle) and segmental necrosis of 
capillaries (right).
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endothelium in vitro. The autoantibodies in individuals with pauci-
immune FNGN commonly recognized and crossreacted with a human 
LAMP-2 epitope with 100% homology to the bacterial adhesin FimH, 
a finding that is of great interest. Further, rats immunized with FimH 
developed pauci-immune FNGN (Figure) and antibodies to rat and 
human LAMP-2. Finally, infections with fimbriated pathogens were 
found to be common before the onset of FNGN. Thus, FimH-triggered 
autoimmunity to LAMP-2 provides a previously unknown molecular 
mechanism for the development of pauci-immune FNGN. (Nat Med 
2008; 14: 1088–1096; doi:10.1038/nm.1874)
Juan Oliver
MYH9 is associated with end-stage 
renal disease in African Americans
African Americans in the United States have markedly higher rates 
of end-stage renal disease (ESRD) than Americans of European 
descent (cumulative lifetime risk of 7.5% versus 2.1%, respectively). 
In this population, the risk of the primary cause of ESRD is 3.8% 
for hypertension, 2.6% for diabetes, 2.3% for glomerulonephri-
tis, and 2.1% for other causes. A kidney disease diagnosed on the 
basis of morphology, called focal and segmental glomerulosclerosis 
(FSGS), is particularly prevalent in subjects of African descent. 
Although lower socioeconomic status and poorer access to health 
care explain some of this excess risk, African Americans appear 
to have greater risk than Americans of European descent even 
after these factors are accounted for. Family studies show cluster-
ing of ESRD independent of hypertension and diabetes, and one 
such study showed stronger aggregation in African Americans. 
Studies attempting to detect susceptibility genes for ESRD and 
other complex diseases are challenging because of the late age 
of disease onset, and because linkage analysis has suggested that 
there are no genes of high penetrance. For these reasons, ESRD 
is an excellent phenotype for genome-wide association analysis, 
an approach that allows unrelated individuals to be studied and 
that has the enhanced power to detect common variants of mod-
est penetrance. In two recent studies, the genetic locus encoding 
nonmuscle myosin heavy chain type II isoform A (MYH9; present 
in podocytes) was found to account for much of the increased 
risk of ESRD in African Americans caused by both hypertension 
and FSGS. Both studies used a type of genome-wide association 
analysis called admixture linkage disequilibrium mapping, which 
is particularly suitable in finding genetic risk alleles that differ in 
frequency between populations. When Kopp et al. performed 
genome scans on 190 African-American individuals with FSGS 
and 222 controls, they identified a region in chromosome 22 with 
a genome-wide lod score of 9.2 and a peak lod of 12.4 centered on 
MYH9.1 Multiple MYH9 single-nucleotide poly morphisms and 
haplotypes were recessively associated with FSGS. This association 
extended to hypertensive ESRD but not to type 2 diabetic ESRD. 
When Kao et al. carried out a genome-wide admixture scan in 1372 
ESRD cases and 806 controls, they found a highly significant asso-
ciation between African ancestry and nondiabetic ESRD (lod score 
= 5.70), but not diabetic ESRD, on chromosome 22q12.2 Each copy 
of the European ancestral allele conferred a relative risk of ESRD 
of 0.50 compared with African ancestry. Again, multiple common 
single-nucleotide polymorphisms in MYH9 were associated with a 
two to four times greater risk of nondiabetic ESRD and accounted 
for a large proportion of the excess risk of ESRD observed in Afri-
can Americans compared with Americans of European descent. 
These important findings suggest that genetic variations at the 
MYH9 locus substantially explain the increased burden of ESRD 
due to hypertension and FSGS among African Americans. Follow-
up studies should clarify the functional consequence of MYH9 risk 
alleles and their population attributable risk. (1Nat Genet 2008; 40: 
1175–1184; doi:10.1038/ng.226. 2Nat Genet 2008; 40: 1185–1192; 
doi:10.1038/ng.232)
Qais Al-Awqati
Prevention of ischemia/ 
reperfusion injury by gene silencing 
of complement C5a receptor
Ischemia/reperfusion (I/R) injury in organ transplantation sig-
nificantly contributes to graft failure and is untreatable by current 
approaches. I/R injury is associated with activation of the com-
plement system, leading to the release of anaphylatoxins, such as 
C5a, and the formation of the membrane attack complex. A new 
study by Zheng et al. shows a novel therapy for kidney I/R injury 
through silencing of the C5a receptor (C5aR) gene using siRNA 
(Figure). Mice were injected with 50 µg of C5aR siRNA 2 days 
before induction of ischemia. Renal ischemia was then induced 
through clamping of the renal vein and artery of the left kidney for 
25 minutes. The therapeutic effects of siRNA on I/R were evaluated 
by assessment of renal function, histopathology, and inflammatory 
cytokines. siRNA targeting C5aR inhibited C5aR gene expression 
both in vitro and in vivo. Administering C5aR siRNA to mice 
reduced levels of serum creatinine and blood urea nitrogen in the 
treated groups. Inhibition of C5aR also diminished in vivo produc-
tion of the proinflammatory cytokine tumor necrosis factor-α and 
the chemokines macrophage inflammatory protein-2 and mouse 
GRO-α, reducing neutrophil influx and cell necrosis in renal tis-
sues. These results demonstrate that siRNA administration repre-
sents a novel approach to preventing renal I/R injury, which could 
be used in a variety of clinical settings if further studied in humans, 
including transplantation and acute tubular necrosis. (Am J Pathol 
2008; 173: 973–980; doi:10.2353/ajpath.2008.080103) 
Marc De Broe
Silencing C5aR with C5aR siRNA in vivo.
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